Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
648 studies found for:    Open Studies | "Carcinoid Tumor"
Show Display Options
Rank Status Study
21 Recruiting Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Metronomic cyclophosphamide;   Drug: Interferon-alpha
22 Recruiting Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Other: Data collection
23 Recruiting Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
24 Recruiting A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Condition: Neuroendocrine Tumours
25 Recruiting Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Lanreotide (Autogel formulation);   Drug: Placebo
26 Recruiting Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
Condition: Neuroendocrine Tumors
Interventions: Drug: Sunitinib;   Drug: Everolimus;   Procedure: Surgery
27 Recruiting Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Condition: Neuroendocrine Tumours
Intervention: Drug: Lanreotide (Autogel formulation) and Temozolomide
28 Not yet recruiting SUV on 68Ga-DOTANOC PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTANOC PET/CT
29 Recruiting Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours
Condition: Neuroendocrine Tumors
Interventions: Procedure: Core Needle Biopsy;   Radiation: Computed Tomography;   Radiation: 18F-FDG-PET;   Procedure: Phlebotomy;   Genetic: Molecular genetic analysis
30 Recruiting A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
Condition: Neuroendocrine Tumors Metastatic to the Liver
Intervention: Drug: Rose bengal disodium
31 Recruiting Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Sulfatinib;   Other: Placebo
32 Not yet recruiting Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival
Condition: Pancreatic Neuroendocrine Tumor
Intervention: Procedure: pancreatectomy
33 Not yet recruiting Phase 2 Study of ONC201 in Neuroendocrine Tumors
Conditions: Recurrent Neuroendocrine Tumor;   Metastatic Neuroendocrine Tumor
Intervention: Drug: ONC201
34 Recruiting Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Condition: Pancreatic Neuroendocrine Tumors
35 Recruiting Personalized PRRT of Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
36 Recruiting The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: sunitinib
37 Recruiting A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Condition: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
Interventions: Drug: lanreotide;   Drug: Placebo
38 Recruiting Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
Conditions: Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
39 Recruiting Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
Conditions: Neuroendocrine Tumors;   Everolimus
Interventions: Drug: everolimus;   Drug: fosbretabulin
40 Recruiting 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Condition: Gastro-entero-pancreatic Neuroendocrine Tumors
Interventions: Drug: Capecitabine;   Drug: Lu-PRRT;   Drug: SS-LAR

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.